<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130311012782N44</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-03-16</date_registration>
      <primary_sponsor>Ghoum University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the efficacy of S-omeprazole alone and with baclofen in the treatment of neonatal reflux</public_title>
      <acronym></acronym>
      <scientific_title>Study of the effect of Esomeprazole and combination of Esomeprazole ppus Baclofen in the treatment of clinical signs of infants reflux</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-04-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45266</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization of patients between the two intervention groups was done using random Allocation Software. In the mentioned software, the sample size is first entered into software for two groups. Then the number of study groups is entered. At the output of the software, a list of two columns is seen, with numbers 1 to 50 (total sample size) distributed in two columns randomly. Patients are divided into two groups according to the time of referral, which is the first patient number 1 and the last patient number 50, Blinding description: This study is done by double blind method . The blinds included in this study include parents of children and person of responsible for data collection . Parents are unaware of the type of drug they are receiving.Also the drugs is prescribed by the researcher for the patients, but the outcome of the study is evaluated by another pediatrician who is unaware of the type of medication the patient is receiving.</study_design>
      <phase>1</phase>
      <hc_freetext>Neonatal Reflux.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Reflux treatment with Esomeprazole made by Rosa Darou Company as intra capsuls granules 1 mg/kg once daily for two weeks. Intervention 2: Intervention group 2:Treatment of reflux with Esomeprazole as intra capsuls granules made by Roz Darou company, 1 mg / kg daily dose plus baclofen tablet (made by Roz darou company) 0.2 mg / kg once daily for 14 days:.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is The plan is owned by the government agency and data cannot be published.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Leila Naderi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 83, 4 alley, 1/1 street, Safashahr</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3713649373</zip>
        <telephone>+98 25 3665 1801</telephone>
        <email>fatemeh.naderi2010@yahoo.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hojatollah Jafari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomini street, Hazrate Masoumeh hospital</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3713649373</zip>
        <telephone>+98 25 3665 1801</telephone>
        <email>ahw_2704@yahoo.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Range age 3 to 12 months
Failure to respond to routine reflux treatments</inclusion_criteria>
      <agemin>3 months</agemin>
      <agemax>12 months</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of hospitalization in neonatal intensive care unit
Birth weight less than 2500 grams
Having an underlying disease such as cerebral palsy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P78.83</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Newborn esophageal reflux</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Reflux treatment with Esomeprazole made by Rosa Darou Company as intra capsuls granules 1 mg/kg once daily for two weeks</i_keyword>
      <i_keyword>Intervention group 2:Treatment of reflux with Esomeprazole as intra capsuls granules made by Roz Darou company, 1 mg / kg daily dose plus baclofen tablet (made by Roz darou company) 0.2 mg / kg once daily for 14 days:</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Newborn esophageal reflux. Timepoint: Before beginning intervention and the end of the first week, second week, first month, second month after intervention. Method of measurement: Investigation of clinical singes.</prim_outcome>
      <prim_outcome>Restlessness. Timepoint: Before beginning intervention and the end of the first week, second week,. Method of measurement: Investigation of clinical singes.</prim_outcome>
      <prim_outcome>Nausea. Timepoint: Before beginning intervention and the end of the first week, second week,. Method of measurement: Investigation of clinical singes.</prim_outcome>
      <prim_outcome>Womitting. Timepoint: Before beginning intervention and the end of the first week, second week,. Method of measurement: Investigation of clinical singes.</prim_outcome>
      <prim_outcome>Respiratory distress. Timepoint: Before beginning intervention and the end of the first week, second week,. Method of measurement: Investigation of clinical singes.</prim_outcome>
      <prim_outcome>Cough. Timepoint: Before beginning intervention and the end of the first week, second week,. Method of measurement: Investigation of clinical singes.</prim_outcome>
      <prim_outcome>Weight loss. Timepoint: Before beginning intervention and the end of the first week, second week,. Method of measurement: Investigation of clinical singes.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ghoum University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-21</approval_date>
        <contact_name>Ethics committee of Qom University of Medical Sciences</contact_name>
        <contact_address>Research faculty, Qom University ofMedical Sciences, Shahi Lavasani street Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
